Catheter Precision, Inc., known in the stock market under the ticker VTAK, is a leading innovator in the field of healthcare, specializing in the manufacture of medical devices. Specifically, this international organization centers its research and development efforts on the creation of high-quality catheters for various medicinal applications.
Based in Mount Olive, New Jersey, Catheter Precision was launched with the primary mission of developing advanced catheter-based technologies designed to radically improve the treatment of arrhythmia. Some of the groundbreaking innovations birthed from this mission include the VMA System and Modulator System. These solutions fully equip medical practices to provide more efficient and effective treatments to patients through better, safer, and user-friendly medical devices.
The company's notable product, the VMA System, uses CT and MRI images of a patient’s heart to create a 3D visual mapping of the heart’s structure. This insightful visualization technique allows doctors to assess heart health more effectively and plan out treatment procedures with increased precision.
The Modulator System, another significant achievement, is credited as the first commercially available system that allows the clinician to control, steer and manipulate diagnostic and therapeutic devices remotely. This effectively decreases any possible risks associated with human error while enhancing the overall accuracy of the process.
Through their commitment to product superiority, Catheter Precision has crafted a longstanding reputation of reliability and excellence within the medical community. They have managed to amalgamate sophisticated technology with clinical needs, offering a transformative approach to cardiac catheter ablation.
Catheter Precision, Inc., places a high stake in advancing medical research and clinical practice. They achieve this through their dedication to revolutionizing the technology used in health care, and prioritizing patient safety and outcomes. By continually delivering innovative medical solutions, Catheter Precision continues to set the bar higher in the field of healthcare technology and product development.
While technological leadership remains a core focus, Catheter Precision also pays close attention to ethical considerations, adhering to robust guidelines in their research, testing, and market delivery processes. Their commitment to upholding rigorous ethical standards buttresses their dedication to offering quality healthcare solutions, making them a trusted and reliable company in the healthcare sector.
The comprehensive services offered by Catheter Precision, Inc., have established their identity as a transformative entity within the medical field and uphold their promise to improve the international standard of cardiovascular treatments. With a solid foundation, extensive expertise, and an unerring focus on research and development, Catheter Precision stands poised to continue leading the industry with innovative and imperative medical technologies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Catheter Precision Inc. is expanding the commercialization of its LockeT device across Latin America after a successful launch in Brazil. The LockeT device, which assists in wound closure after percutaneous venous punctures, has been adopted by six hospitals in Brazil since its August launch. The company is now pursuing opportunities in Argentina, Chile, Colombia, and other markets, leveraging an experienced cardiology group for support.
Flyte, a subsidiary of Catheter Precision, Inc. (NYSE: VTAK), announced that it has surpassed 10,000 registered consumer accounts on its WebApp, with new account creation accelerating significantly in August. Despite this milestone, VTAK shares dipped by 2.8%. The company highlighted robust growth in new accounts, with nearly a quarter of its total accounts created in the last 30 days.
Flyte, a subsidiary of Catheter Precision, Inc., has announced a strategic partnership with The Nucleus Network to support its inaugural "The Nucleus" event. This collaboration positions Flyte at the center of a premier community of founders, investors, and operators, aligning with Flyte's strategy to expand its presence and become a preferred private aviation provider. The event, scheduled for August 15th, will bring together approximately 200 key individuals for networking and relationship building.